| P2093 | author name string | Sidney Croul | |
| | Donya Aref | |
| P2860 | cites work | Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome | Q24336457 |
| | Dissecting the genomic complexity underlying medulloblastoma | Q24621907 |
| | Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system | Q28270384 |
| | Subgroup-specific structural variation across 1,000 medulloblastoma genomes | Q28271811 |
| | beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee | Q28279527 |
| | Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma | Q28284093 |
| | ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration | Q28284396 |
| | Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 |
| | Subtypes of medulloblastoma have distinct developmental origins | Q28300616 |
| | Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog | Q28586621 |
| | Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations | Q30040534 |
| | Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma | Q30156001 |
| | SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42 | Q30423594 |
| | CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 |
| | Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features | Q33366431 |
| | Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. | Q33539849 |
| | Mutations in SUFU predispose to medulloblastoma | Q34133729 |
| | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 |
| | Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. | Q34285237 |
| | Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma | Q34398276 |
| | The molecular basis of Turcot's syndrome | Q34662365 |
| | Rapid diagnosis of medulloblastoma molecular subgroups | Q34764793 |
| | Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma | Q43667669 |
| | N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. | Q45118490 |
| | Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial | Q45120061 |
| | The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone | Q45121434 |
| | Treatment of early childhood medulloblastoma by postoperative chemotherapy alone | Q46367739 |
| | Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression | Q46507354 |
| | Molecular analysis of the lissencephaly gene 1 (LIS-1) in medulloblastomas | Q48063530 |
| | Structural chromosomal abnormalities in human medulloblastoma | Q48125276 |
| | Chromosome abnormalities in pediatric brain tumors | Q48135652 |
| | Large-cell medulloblastomas. A distinct variant with highly aggressive behavior | Q48459892 |
| | Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features | Q48805693 |
| | High-resolution deletion mapping of chromosome arm 17p in childhood primitive neuroectodermal tumors reveals a common chromosomal disruption within the Smith-Magenis region, an unstable region in chromosome band 17p11.2. | Q48822376 |
| | Epidemiology of adult medulloblastoma | Q50638609 |
| | Medulloblastoma. A report of 201 cases with emphasis on the relationship of histologic variants to survival | Q51120057 |
| | Role of Wnt pathway in medulloblastoma oncogenesis. | Q52547248 |
| | MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. | Q53201641 |
| | Stratification of medulloblastoma on the basis of histopathological grading. | Q53255752 |
| | Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. | Q53286039 |
| | Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. | Q53300055 |
| | An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. | Q54427712 |
| | Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. | Q55468802 |
| | Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. | Q55469539 |
| | Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. | Q55473840 |
| | "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. | Q55474949 |
| | Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. | Q55476488 |
| | Sporadic medulloblastomas contain oncogenic beta-catenin mutations. | Q55477948 |
| | Correlation between polysialic-neural cell adhesion molecule levels in CSF and medulloblastoma outcomes. | Q55479479 |
| | Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. | Q55480515 |
| | Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute. | Q55481382 |
| | Medulloblastoma: survey of factors possibly influencing the prognosis. | Q55489984 |
| | Nuclear localization and mutation of beta-catenin in medulloblastomas | Q73662960 |
| | Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features | Q34866372 |
| | Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes | Q34977375 |
| | Anaplasia and grading in medulloblastomas. | Q35208292 |
| | APC mutations in sporadic medulloblastomas | Q35745470 |
| | Clonal selection drives genetic divergence of metastatic medulloblastoma | Q35784926 |
| | Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas | Q35796194 |
| | Novel mutations target distinct subgroups of medulloblastoma. | Q36143877 |
| | Morphing into cancer: the role of developmental signaling pathways in brain tumor formation | Q36205991 |
| | Functional genomics identifies drivers of medulloblastoma dissemination | Q36296016 |
| | Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions | Q36451030 |
| | Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups | Q36460209 |
| | Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours | Q36620330 |
| | Medulloblastoma comprises four distinct molecular variants | Q36920479 |
| | Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma | Q37002410 |
| | An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). | Q37177897 |
| | Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma | Q38340521 |
| | The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma. | Q38352855 |
| | ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. | Q38358939 |
| | MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group | Q38456964 |
| | Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma | Q39382947 |
| | MicroRNA-21 suppression impedes medulloblastoma cell migration | Q39503647 |
| | Calmodulin-kinases regulate basal and estrogen stimulated medulloblastoma migration via Rac1. | Q39627627 |
| | Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis | Q39828521 |
| | c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. | Q39862140 |
| | The flavonols quercetin, kaempferol, and myricetin inhibit hepatocyte growth factor-induced medulloblastoma cell migration. | Q39879515 |
| | The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells | Q39904552 |
| | An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma | Q39910333 |
| | Integrins mediate adhesion of medulloblastoma cells to tenascin and activate pathways associated with survival and proliferation | Q39939384 |
| | Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 |
| | Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease | Q40781851 |
| | Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors | Q40795419 |
| | Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome | Q40851117 |
| | Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours | Q41099186 |
| | Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management | Q41449272 |
| | Genetics of pediatric central nervous system tumors | Q41667932 |
| | Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 | Q42031842 |
| | Sporadic medulloblastomas contain PTCH mutations. | Q42434884 |
| | Basal cell carcinomas in mice overexpressing sonic hedgehog | Q42437252 |
| | Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. | Q42439709 |
| | Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. | Q42440473 |
| | A frequent activated smoothened mutation in sporadic basal cell carcinomas | Q42467910 |
| P433 | issue | 4 | |
| P921 | main subject | medulloblastoma | Q1333608 |
| P304 | page(s) | 377-385 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | CNS oncology | Q26842350 |
| P1476 | title | Medulloblastoma: recurrence and metastasis | |
| P478 | volume | 2 | |